Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges

Immune checkpoint inhibitors (ICIs) are the most notable breakthrough in tumor treatment. ICIs has been widely used in tumor patients, but its wide range of immune-related adverse events (irAEs) should not be ignored. irAEs can be involved in any organ system, including immune-related cardiotoxicity...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lu Gan, Demin Liu, Yanan Ma, Xuening Chen, Aihui Dai, Sihan Zhao, Xiaoxue Jin, Guoqiang Gu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-08-01
coleção:	Frontiers in Pharmacology
Assuntos:	cardiotoxicity immune checkpoint inhibitors oncotherapy tumor immunotherapy myocarditis
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2022.962596/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!